• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CARRA-VID预后评分的开发与验证:基于C反应蛋白与白蛋白比值、红细胞分布宽度和年龄的住院COVID-19患者预后评分

Development and Validation of the CARRA-VID Prognostic Score: C Reactive Protein to Albumin Ratio, Red Blood Cell Distribution Width and Age-Based Score for Prognostication of Hospitalized COVID-19 Patients.

作者信息

Lucijanic Marko, Piskac Zivkovic Nevenka, Busic Nikolina, Stojic Josip, Atic Armin, Derek Lovorka, Krecak Ivan, Barsic Bruno, Luksic Ivica

机构信息

Division of Hematology, Internal Medicine Department, University Hospital Dubrava, 10000 Zagreb, Croatia.

Scientific Research and Translational Medicine Department, University Hospital Dubrava, 10000 Zagreb, Croatia.

出版信息

Viruses. 2025 Apr 27;17(5):629. doi: 10.3390/v17050629.

DOI:10.3390/v17050629
PMID:40431641
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12115730/
Abstract

Patients hospitalized due to coronavirus disease 2019 (COVID-19) usually present with severe or critical intensity of symptoms, accompanied by a marked systemic inflammatory response. Classical inflammatory biomarkers, C-reactive protein (CRP), albumin, and red blood cell distribution width (RDW) have previously been reported to be prognostic in hospitalized COVID-19 patients. We performed a retrospective analysis of two large cohorts (2305 and 2328 patients, respectively) of consecutive hospitalized COVID-19 patients with mostly severe and critical symptoms admitted to the tertiary referral center to develop and validate a prognostic score for 30-day mortality based on CRP-to-Albumin-Ratio (CAR), RDW, and age (termed CARRA-VID score). We identified 6 prognostic categories: very low, low, intermediate-1, intermediate-2, high, and very high risk, with corresponding 30-day mortality rates of 2.7%, 10.7%, 30.9%, 47.1%, 61.9%, and 89.7%, respectively. Effective risk stratification was validated in an independent cohort of patients and remained independent of the World Health Organization-defined disease severity and other commonly utilized risk scores. Additional analyses evaluated the score across different time periods dominated by distinct viral variants. We also present a simplified 3-tiered version of the score. A Microsoft Excel Workbook containing the score calculator is provided.

摘要

因2019冠状病毒病(COVID-19)住院的患者通常症状严重或危急,伴有明显的全身炎症反应。经典炎症生物标志物,如C反应蛋白(CRP)、白蛋白和红细胞分布宽度(RDW),此前已被报道对COVID-19住院患者具有预后价值。我们对一家三级转诊中心收治的两组连续住院的COVID-19患者(分别为2305例和2328例)进行了回顾性分析,这些患者大多症状严重或危急,旨在基于CRP与白蛋白比值(CAR)、RDW和年龄(称为CARRA-VID评分)制定并验证一个30天死亡率的预后评分。我们确定了6个预后类别:极低、低、中-1、中-2、高和极高风险,对应的30天死亡率分别为2.7%、10.7%、30.9%、47. I%、61.9%和89.7%。有效的风险分层在一个独立的患者队列中得到验证,并且独立于世界卫生组织定义的疾病严重程度和其他常用的风险评分。进一步分析评估了该评分在由不同病毒变体主导的不同时间段的情况。我们还给出了该评分的简化三层版本。提供了一个包含评分计算器的Microsoft Excel工作簿。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/7419177ae2b2/viruses-17-00629-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/70b885c6141b/viruses-17-00629-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/6a2ae3551745/viruses-17-00629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/7419177ae2b2/viruses-17-00629-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/70b885c6141b/viruses-17-00629-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/6a2ae3551745/viruses-17-00629-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f1/12115730/7419177ae2b2/viruses-17-00629-g003.jpg

相似文献

1
Development and Validation of the CARRA-VID Prognostic Score: C Reactive Protein to Albumin Ratio, Red Blood Cell Distribution Width and Age-Based Score for Prognostication of Hospitalized COVID-19 Patients.CARRA-VID预后评分的开发与验证:基于C反应蛋白与白蛋白比值、红细胞分布宽度和年龄的住院COVID-19患者预后评分
Viruses. 2025 Apr 27;17(5):629. doi: 10.3390/v17050629.
2
Accuracy of routine laboratory tests to predict mortality and deterioration to severe or critical COVID-19 in people with SARS-CoV-2.常规实验室检测对预测 SARS-CoV-2 感染者死亡和病情恶化为重症或危重症 COVID-19 的准确性。
Cochrane Database Syst Rev. 2024 Aug 6;8(8):CD015050. doi: 10.1002/14651858.CD015050.pub2.
3
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
4
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.用于治疗 COVID-19 的 SARS-CoV-2 中和单克隆抗体。
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
5
Interventions for palliative symptom control in COVID-19 patients.干预措施以控制 COVID-19 患者的姑息症状。
Cochrane Database Syst Rev. 2021 Aug 23;8(8):CD015061. doi: 10.1002/14651858.CD015061.
6
Interleukin-6 blocking agents for treating COVID-19: a living systematic review.白细胞介素 6 阻断剂治疗 COVID-19:一项实时系统评价。
Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013881. doi: 10.1002/14651858.CD013881.pub2.
7
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
8
Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
9
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19.SARS-CoV-2 中和单克隆抗体预防 COVID-19。
Cochrane Database Syst Rev. 2022 Jun 17;6(6):CD014945. doi: 10.1002/14651858.CD014945.pub2.
10
Liver Scores in the Prognostication of COVID-19 Patients.肝脏评分在COVID-19患者预后评估中的作用
Viruses. 2025 Mar 19;17(3):444. doi: 10.3390/v17030444.

本文引用的文献

1
Microenvironmental dynamics in steady-state and stress erythropoiesis.稳态和应激性红细胞生成中的微环境动态变化。
Blood Sci. 2025 Feb 11;7(1):e00219. doi: 10.1097/BS9.0000000000000219. eCollection 2025 Jan.
2
Accounting for Red Cell Distribution Width Improves Risk Stratification by Commonly Used Mortality/Deterioration Risk Scores in Adult Patients Hospitalized Due to COVID-19.纳入红细胞分布宽度可改善因新冠肺炎住院的成年患者常用死亡率/病情恶化风险评分的风险分层。
Life (Basel). 2024 Oct 5;14(10):1267. doi: 10.3390/life14101267.
3
Erythropoiesis: insights from a genomic perspective.
红细胞生成:从基因组角度看。
Exp Mol Med. 2024 Oct;56(10):2099-2104. doi: 10.1038/s12276-024-01311-1. Epub 2024 Oct 1.
4
Thromboinflammation in COVID-19: Unraveling the interplay of coagulation and inflammation.新型冠状病毒肺炎中的血栓炎症反应:解析凝血与炎症的相互作用。
Medicine (Baltimore). 2024 Jul 12;103(28):e38922. doi: 10.1097/MD.0000000000038922.
5
The Complete Blood Count: Increasing Its Precision and Impact.全血细胞计数:提高其精确性与影响力。
Ann Intern Med. 2023 Aug;176(8):eL230164. doi: 10.7326/L23-0164.
6
Role of serum C-reactive protein (CRP)/Albumin ratio in predicting the severity of acute pancreatitis: A retrospective cohort.血清C反应蛋白(CRP)/白蛋白比值在预测急性胰腺炎严重程度中的作用:一项回顾性队列研究。
Ann Med Surg (Lond). 2022 Sep 21;82:104715. doi: 10.1016/j.amsu.2022.104715. eCollection 2022 Oct.
7
COVID-19 infection: an overview on cytokine storm and related interventions.COVID-19 感染:细胞因子风暴及相关干预措施概述。
Virol J. 2022 May 26;19(1):92. doi: 10.1186/s12985-022-01814-1.
8
Gradual increase in red cell distribution width is similarly prognostic for in-hospital mortality in both anemic and non-anemic COVID-19 patients.红细胞分布宽度的逐渐增加对贫血和非贫血COVID-19患者的院内死亡率同样具有预后意义。
J Med Virol. 2022 Aug;94(8):3509-3511. doi: 10.1002/jmv.27785. Epub 2022 Apr 21.
9
Red cell distribution width is a potent prognostic parameter for in-hospital and post-discharge mortality in hospitalized coronavirus disease 2019 patients: a registry-based cohort study on 3941 patients.红细胞分布宽度是住院的 2019 年冠状病毒病患者住院期间和出院后死亡率的一个强有力的预后参数:基于登记的队列研究,涉及 3941 例患者。
Croat Med J. 2022 Feb 28;63(1):44-52. doi: 10.3325/cmj.2022.63.44.
10
The associations of age, sex, and comorbidities with survival of hospitalized patients with coronavirus disease 2019: data from 4014 patients from a tertiary-center registry.年龄、性别和合并症与 COVID-19 住院患者生存的关系:来自一个三级中心登记处的 4014 例患者的数据。
Croat Med J. 2022 Feb 28;63(1):36-43. doi: 10.3325/cmj.2022.63.36.